Health Care [ 8/12 ] | Biotechnology [ 51/73 ]
NASDAQ | Common Stock
TScan Therapeutics, Inc., a clinical-stage biotechnology company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States.
The company's lead product candidates include TSC-100 and TSC-101 for the treatment of patients with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and acute lymphoblastic leukemia (ALL) in patients undergoing allogeneic hematopoietic cell transplantation (HCT) is in Phase I clinical trial, as well as eliminates residual disease and promotes donor chimerism.
It also advanced TS-102 into IND-enabling activities.
In addition, the company develops TSC-200, TSC-201, TSC-202, TSC-203, and TSC-204, which are in Phase 1 clinical trial, for the treatment of solid tumors.
It has collaboration agreements with Novartis Institutes for BioMedical Research, Inc. to discover and develop novel TCR-T therapies; and Amgen Inc. to identify antigens recognized by T cells in patients with Crohn's disease using TargetScan, a proprietary target discovery platform.
TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Aug 12, 25 | -0.28 Increased by 0.00% | -0.33 Increased by +15.15% |
| May 6, 25 | -0.60 Decreased by -87.50% | -0.28 Decreased by -114.29% |
| Mar 5, 25 | -0.30 Decreased by -42.86% | -0.29 Decreased by -3.45% |
| Nov 12, 24 | -0.25 Decreased by -4.17% | -0.31 Increased by +19.35% |
| Aug 12, 24 | -0.28 Increased by +45.10% | -0.28 |
| May 13, 24 | -0.32 Increased by +65.59% | -0.26 Decreased by -23.08% |
| Mar 6, 24 | -0.21 Increased by +73.08% | -0.29 Increased by +27.59% |
| Nov 9, 23 | -0.24 Increased by +64.18% | -0.45 Increased by +46.67% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Jun 30, 25 | 3.08 M Increased by +473.88% | -36.95 M Decreased by -16.71% | Decreased by -1.20 K% Increased by +79.66% |
| Mar 31, 25 | 2.17 M Increased by +283.57% | -34.13 M Decreased by -13.22% | Decreased by -1.57 K% Increased by +70.48% |
| Dec 31, 24 | 665.00 K Decreased by -90.78% | -35.81 M Decreased by -82.58% | Decreased by -5.38 K% Decreased by -1.88 K% |
| Sep 30, 24 | 1.05 M Decreased by -73.01% | -29.89 M Decreased by -29.96% | Decreased by -2.85 K% Decreased by -381.56% |
| Jun 30, 24 | 536.00 K Decreased by -82.97% | -31.66 M Decreased by -31.67% | Decreased by -5.91 K% Decreased by -673.34% |
| Mar 31, 24 | 566.00 K Decreased by -91.68% | -30.14 M Decreased by -33.59% | Decreased by -5.33 K% Decreased by -1.51 K% |
| Dec 31, 23 | 7.21 M Increased by +721.00 K% | -19.61 M Decreased by -4.34% | Decreased by -271.99% Increased by +99.99% |
| Sep 30, 23 | 3.89 M Increased by +15.58% | -23.00 M Decreased by -41.56% | Decreased by -591.64% Decreased by -22.48% |